Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice by Crowley, James et al.
Genome-Wide Association Mapping Of Loci for Antipsychotic-
Induced Extrapyramidal Symptoms in Mice
James J. Crowley1,2, Yunjung Kim1, Jin Peng Szatkiewicz1, Amanda L. Pratt1, Corey R.
Quackenbush1, Daniel E. Adkins3, Edwin van den Oord3, Molly A. Bogue4, Hyuna Yang4,
Wei Wang5, David W. Threadgill6, Fernando Pardo-Manuel de Villena1, Howard L. McLeod2,
and Patrick F. Sullivan, MD FRANZCP1,7
1Department of Genetics; University of North Carolina at Chapel Hill, NC, USA
2Institute for Pharmacogenomics and Individualized Therapy; UNC at Chapel Hill, NC, USA
3Center for Biomarker Research & Personalized Med; Virginia Commonwealth University,
Richmond
4The Jackson Laboratory; Bar Harbor, ME, USA
5Department of Computer Science; University of North Carolina at Chapel Hill, NC, USA
6Department of Genetics, North Carolina State University, Raleigh, NC
7Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
Abstract
Tardive dyskinesia (TD) is a debilitating, unpredictable and often irreversible side effect resulting
from chronic treatment with typical antipsychotic agents such as haloperidol. TD is characterized
by repetitive, involuntary, purposeless movements primarily of the orofacial region. In order to
investigate genetic susceptibility to TD, we used a validated mouse model for a systems genetics
analysis geared toward detecting genetic predictors of TD in human patients. Phenotypic data
from 27 inbred strains chronically treated with haloperidol and phenotyped for vacuous chewing
movements were subject to a comprehensive genomic analysis involving 426,493 SNPs, 4,047
CNVs, brain gene expression, along with gene network and bioinformatic analysis. Our results
identified ~50 genes that we expect to have high prior probabilities for association with
haloperidol-induced TD, most of which have never been tested for association with human TD.
Among our top candidates were genes regulating the development of brain motor control regions
(Zic4, Nkx6-1), glutamate receptors (Grin1, Grin2a), and an indirect target of haloperidol (Drd1a)
that has not been as well studied as the direct target, Drd2.
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First-generation or “typical” antipsychotics (prototype haloperidol) can cause a number of
motor side effects that are collectively termed extrapyramidal syndromes (EPS) (Dayalu and
Chou 2008; Hsin-tung E and Simpson 2000). Of all patients who initiate treatment, ~40%
experience restlessness, involuntary spasms or muscular rigidity in the first few weeks and
these symptoms are alleviated to varying degrees by anticholinergic agents (Simpson 1970).
Of all patients who sustain long-term treatment (> 3 months), ~35% develop the EPS
syndrome tardive dyskinesia (TD) (Dayalu and Chou 2008; Hsin-tung E and Simpson 2000).
TD is characterized by repetitive, involuntary and purposeless movements, primarily of the
orofacial region (e.g., chewing movements and tongue protrusion) (Crane 1968). Of all
individuals who develop TD, it is irreversible in ~50% of cases (Soares-Weiser and
Fernandez 2007b) and there is currently no validated and widely accepted treatment
(Tandon et al. 2008). Therefore, the physician cannot predict whether a patient will develop
TD and, without efficacious treatments, a large number of patients are left with a disfiguring
condition.
While familial occurrence of tardive dyskinesia has been observed in a few small studies
(Muller et al. 2001; O’Callaghan et al. 1990; Yassa and Ananth 1981), there are no
heritability estimates for susceptibility to TD in humans. Despite lack of known heritability,
a number of candidate genes have been tested for associations with TD. The results are
generally inconsistent. The most encouraging data are for DRD3, HTR2A, HTR2C, and
CYP2D6 with positive meta-analyses for each (Bakker et al. 2006; Lerer et al. 2005;
Patsopoulos et al. 2005; Reynolds et al. 2005). Negative results have been obtained for
DRD2, DRD4, COMT, MAOA, MAOB, and enzymes related to oxidative stress (Herken et
al. 2003; Kaiser et al. 2002; Lai et al. 2005; Lee et al. 2007; Matsumoto et al. 2004). Many
of these studies suffered from the limitations of examining just one gene at a time, and
usually only a single genetic variant, and suboptimal power due to small sample sizes
(n<500). We have completed a genome-wide association study (GWAS) of TD by analyzing
492,900 single nucleotide polymorphisms (SNPs) in 214 TD cases and 524 controls with
schizophrenia, and no association exceeded chance expectations (Aberg et al. 2010).
Because of limited progress with human pharmacogenomic studies, we explored the
potential of a complementary mouse-then-human experimental paradigm (Harrill et al. 2009;
Rusyn et al. 2010). We exposed diverse inbred mouse strains to human-like steady-state
drug concentrations and measured outcomes of relevance to TD. All strains were previously
genotyped using a dense single-nucleotide polymorphism (SNP) chip (Yang et al. 2009b),
allowing genetic mapping in silico. Human orthologs of genomic regions strongly
implicated in mouse can then be used to reduce the genetic search space in humans to
determine whether the association replicates across species.
After chronic treatment with typical antipsychotics, rodents show purposeless mouth
openings in the vertical plane (vacuous chewing movements, VCMs)(Waddington et al.
1983). VCMs are a phenotypically and pharmacologically valid animal model of TD that
has been used for decades by behavioral pharmacologists (Turrone et al. 2003; Turrone et al.
2002). A large body of research has shown that haloperidol-induced VCM closely mimic
nearly every characteristic of human TD (Soares-Weiser and Fernandez 2007a). In a recent
study from our laboratory (Crowley et al. 2010), we exposed 27 genetically inbred mouse
strains to standardized doses of haloperidol for 120 days in order to calculate heritability and
to identify optimal phenotypes for genetic association mapping. This study yielded five
critical pieces of information. First, we showed that it is possible to deliver human-like
steady state concentrations of haloperidol to diverse mouse strains in a reliable manner with
implantable drug pellets. Second, we demonstrated that haloperidol plasma concentrations
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are highly variable between inbred strains with heritability estimates of ~0.7 and are not
influenced by potential confounders such as the dose implanted or body mass. Third, we
observed marked behavioral changes across multiple domains. Four measures of activity in
the open field, rigidity on an inclined screen (a measure of EPS), and four measures of
orofacial movement all exhibited, on average, marked changes following haloperidol
exposure. Crucially, these measures were independent of haloperidol plasma level and strain
was again the major predictor of phenotypic variation. Fourth, we observed that the
behavioral domains we assessed were not discrete constructs but rather loaded onto two
factors (Table S1). One factor loaded primarily on antipsychotic-induced changes in open
field activity (“OFA”), while the other loaded primarily on haloperidol-induced orofacial
movements (“Orofacial”). Finally, we found high heritabilities for haloperidol-induced
effects on VCMs, activity in the open field, and EPS. Heritabilities for each of these
phenotypes exceeded 75%, and heritability of the factors OFA and Orofacial were ~0.9,
after incorporation of the longitudinal nature of the design (Crowley et al. 2010).
In the current study, we perform genetic association mapping of the highly heritable factors
from Crowley et al. (“OFA” and “Orofacial”) (Crowley et al. 2010), haloperidol levels and a
composite measure of EPS. A comprehensive genomic analysis approach was taken,
including tests of association with genome-wide SNPs, biological pathways, copy number
variants (CNVs) and gene expression from the brains of the animals tested.
Methods And Materials
Phenotypic data
The collection of the phenotypic data for this study is described in detail in Crowley et al.
(Crowley et al. 2010). For GWAS mapping, we chose four phenotypes from Crowley et al.:
1) a principal component loading primarily on antipsychotic-induced changes in open field
activity (“OFA”), 2) a principal component loading primarily on antipsychotic-induced
changes in orofacial movements (“Orofacial”), 3) the log10 transformation of plasma
haloperidol levels 30 days after drug pellet implantation (“HAL30”) and 4) a basic linear
unbiased predictor of changes in inclined screen rigidity across 120 days of drug treatment
(“EPS”), a commonly used measure of extrapyramidal symptoms in the literature (Chipkin
et al. 1988).
Animals
All testing procedures were conducted in strict compliance with the Guide for the Care and
Use of Laboratory Animals and approved by the Institutional Animal Care and Use
Committee of the University of North Carolina. Male mice (aged 8-10 weeks at the start of
testing) from 27 inbred strains (N = 5-9 mice/strain) were obtained from the Jackson
Laboratory (Bar Harbor, ME) through the Mouse Phenome Project (Bogue and Grubb
2004). A total of 22 classical and 5 wild-derived strains were examined (Table S2). Animals
were maintained on a 12h light:12h dark schedule with lights on at 0700. The housing room
was maintained at 20-24°C with 40-50% relative humidity. Mice were housed in standard 20
cm × 30 cm ventilated polycarbonate cages with laboratory grade Bed-O-Cob bedding.
Water and Purina ProLab IsoPro 3000 were available ad libitum. All mice were group-
housed (maximum of five per cage) except that BALB/cByJ, CAST/EiJ, and SJL/J mice
were separated due to fighting after 7, 10 and 13 weeks of housing, respectively. All
phenotypes were measured on days 0, 30, 60, 90 and 120 relative to drug treatment (day 1).
Antipsychotic exposure
Slow release haloperidol pellets (3.0 mg/kg/day; Innovative Research of America; Sarasota,
FL) (Fleischmann et al. 2002) designed for 60 days of continuous release were implanted
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subcutaneously with a trocar under two minutes of isoflurane anesthesia. Blood plasma was
collected via tail nick for drug concentration assays after 30, 60, 90 and 120 days of
exposure to haloperidol. Human-like steady-state concentrations of haloperidol (3.75-19 ng/
ml) (Hsin-Tung and Simpson 2000) were achieved in 98% of mice. Figure S1 shows
haloperidol plasma levels for each strain across the duration of this study.
Scoring VCMs
High-resolution digital videotapes of orofacial behavior were made by modifying the
method of Tomiyama et al. (Tomiyama et al. 2001) (Figure S2). Each mouse was placed in a
restrictor device for 25 minutes, and the final 15 minutes were scored for orofacial
movement phenotypes: tongue protrusions, overt chewing movements, subtle chewing
movements and jaw tremors.
Open field activity
Extrapyramidal side effects may appear as general motor deficits in mice. Therefore,
spontaneous locomotor activity in the open field (Crawley 1985) was measured for 1 hour
using an automated apparatus (Accuscan Instruments, Columbus, OH). Four phenotypes
were extracted from these activity data: total distance traveled (cm), vertical activity,
stereotypy, and time spent in the central region of the chamber (percent of total time; central
20cm × 20cm).
Extrapyramidal side effects (EPS)
The inclined screen test (Barnes et al. 1990) was used as an index of Parkinsonian rigidity
and sedation. Mice were placed on a wire mesh screen inclined at 45° and the latency to
move all four paws was recorded (maximum of 300 seconds).
Phenotypic statistical analysis
Linear mixed effects models (Crowley et al. 2010) were used to decompose phenotype
variances for the calculation of heritability and to assess the significance of covariate fixed
effects (R 2.6.0 and Stata 9.2). Heritability was calculated using intra-class correlation
coefficients. The heritabilities of the over-time trajectories in haloperidol-induced movement
disorder phenotypes were assessed using an extension of the mixed model for behavioral
genetic analysis (Goldstein 1995). We applied factor analysis to examine the factor structure
of the mouse-specific response trajectories (MPlus 5.21) (Joreskog 1969; Muthén and
Muthén 2003; Van Prooijen and Van Der Kloot 2001) and individual response phenotype
trajectories were decomposed into strain- and mouse-level components, with heritabilities
calculated as the ratio of strain-level variance to strain-level + mouse-level variance (Figure
S3).
SNP genotypes
All 27 strains were genotyped at the Jackson Laboratory using the Affymetrix Mouse
Diversity Array (Yang et al. 2009a) which contains 623,124 SNPs. Prior to association
mapping, we removed singletons, heterozygous or missing genotypes, and highly variable
probes suggestive of variation within the probe sequence (Yang et al. 2009a). A total of
426,493 SNPs remained for association analysis following quality control.
Association mapping
Due to the population substructure among commercially-available inbred strains, it is
critically important to avoid false associations owing to population stratification. Therefore,
a three-step process was used for genome-wide association mapping in an effort to reduce
the effect of population stratification and increase confidence in mapped loci. First, we used
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EMMA (Efficient Mixed Model Association) (Kang et al. 2008) to assess evidence of
association between each SNP and phenotype. EMMA implements a linear mixed model to
account for population structure and genetic relatedness among strains by estimating the
pair-wise relatedness between all individuals and fitting these to the phenotype vector. We
controlled Type I multiple testing error using permutation by shuffling the strain label while
keeping the genotype vectors intact (1,000 permutations). The percentiles of the minimum
p-value per permutation were used to determine genome-wide significance thresholds
adjusting for multiple testing. Thresholds were 3.4E-8, 1.6E-6, 8.7E-13, and 9.5E-6 for
OFA, Orofacial, EPS, and HAL30, respectively. As a check, EMMA was applied after
removing the five wild-derived strains as population stratification artifacts are more likely
with these genetically divergent strains (Kang et al. 2008). Second, we used TreeQA (Pan et
al. 2009), to examine the reproducibility of EMMA results. TreeQA is a quantitative
genome-wide association mapping algorithm which uses local phylogenies constructed in
genomic regions exhibiting no evidence of historical recombination. Finally, to confirm the
robustness of allelic effects, we performed a univariate test (Wilcoxin ranked-sum) using
single SNP genotypes as predictors of the primary phenotypic values.
Pathway analysis
We used Ingenuity Pathway Analysis (v6.0) which contains curated biological interactions
and functional annotation. As input, we selected the top 1% of genes in each phenotype
ranked by minimum p-value. The p-value cutoffs for the top 1% genes were 0.00057,
0.000274, 8.04E-7, and 0.000321 for OFA, Orofacial, EPS, and HAL30.
Bioinformatic analysis
First, we selected all SNPs with EMMA p ≤ 0.0001. Second, we annotated each SNP using
UCSC’s KnownGene (Fujita et al. 2011; Hsu et al. 2006), mouse QTL data (Blake et al.
2011), OMIM (McKusick 2007), The Jackson Laboratory’s Mouse Phenotype Database
(Blake et al. 2011) and The Sanger Institute Mouse SNPs database
(www.sanger.ac.uk/resources/mouse/genomes). We extracted information from the first
three databases when the position of each SNP maps within the interval of start and end
position of each entry. For the QTL database, we chose a window of ± 5 Mb, since QTL in
standard crosses are not mapped to high resolution. The Sanger SNPs database has full
genome sequence for 13 of the 27 strains we studied.
CNV analysis
The same Mouse Diversity Array .CEL files that were used to genotype SNPs were used for
CNV calling. We analyzed hybridization intensity data from 622,995 SNPs and 597,225
exon probe sets using PennCNV (Wang et al. 2007) to generate an initial set of CNVs calls.
We then applied a multi-step quality control procedure (remove CNVs that overlap array
gaps, remove small, low confidence, or sparse CNVs) to derive the most confident call set (a
total of 4,047 CNV regions were predicted across 26 strains). We do not currently know the
level of false negative and false positive CNV calls in this dataset, but are currently using an
independent methodology to examine the validity of these calls. This CNV dataset will be
the focus of a future publication. We used binary CNV genotypes for genome-wide
association with EMMA. Finally, we checked for the presence of CNVs in regions with
EMMA SNPs with p < 0.0001 for each phenotype.
Gene expression analysis
The animals used for gene expression are the same ones described in detail in Crowley et al.
(Crowley et al. 2010), in which each animal was treated with haloperidol for 120 days and
behaviorally phenotyped. At the completion of drug treatment, whole brain was collected
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from 92 animals (25 strains, average of 4 brains/strain, Table S2) and total RNA was
extracted using an automated Maxwell 16 Instrument (Promega; Madison, WI). All samples
were processed according to manufacturer’s instructions and hybridized to an Affymetrix
Mouse Gene 1.1 ST 96-Array Plate (Affymetrix; Santa Clara, CA). Before analysis, we
removed probes containing a known genetic variant from Sanger Institute re-sequencing.
We used the RMA method for background adjustment, quantile normalization, and to
estimate target and probe effects. Using the probe-set summarized data, we ran a simple
linear regression model to test whether changes of expression levels were associated with
phenotype. For pathway analysis, we used SAFE (Barry et al. 2005), a two-stage,
permutation-based method that accounts for the unknown correlation among genes. Finally,
we calculated association between SNP genotype and gene expression levels for EMMA
SNPs with p<0.0001. We collected all probe sets within 1Mb of these SNPs, stratified gene
expression values by SNP genotype and tested for a significant expression difference
between the two genotypes using t-test. For each phenotype, we calculated adjusted p-values
using false discovery rate.
Results
Phenotypic data
We first selected four phenotypes from Crowley et al (Crowley et al. 2010) with optimal
properties for genetic analysis. To this end, we chose one trait with high heritability (all
>0.8) for four domains of primary interest: VCMs (Orofacial), pharmacokinetics (HAL30),
rigidity (EPS) and open field activity (OFA). Figure 1 shows the 27-strain distribution for
each of these phenotypes. First, the five wild-derived strains (CAST, PWK, WSB, MSM,
MOLF) were evenly distributed among Orofacial and HAL30, but tended to be less affected
by haloperidol in the inclined screen and open field activity tests. Since this could cause
spurious GWAS results owing to population stratification, we decided to run GWA for all
traits with and without wild-derived strains. Second, strains derived from New Zealand
(NZL, NZO, NZW) were susceptible to haloperidol-induced rigidity on the inclined screen
test (Figure 1C) and had higher levels of haloperidol (Figure 1B). For EPS we still found an
overabundance of GWAS peaks with p <1×10−5, suggesting residual stratification effects.
To test this, we ran EMMA with the three New Zealand strains removed and found the top
peak to be just 3.1×10−5 (Figure S4), confirming our suspicion. However, since we believe
the high EPS susceptibility of the New Zealand strains is a true genetic effect, we decided to
leave them in the analysis, calculate a permutation-based genome-wide significance level for
each phenotype (see below) and focus follow-up analyses on the top 1% of SNP associated
loci. Finally, we found a great deal of variability among the eight Collaborative Cross
(Churchill et al. 2004) parental strains (A/J, C57BL6/J, 129S1, NOD, NZO, CAST, PWK,
WSB) for each of our phenotypes, indicating that this population would be appropriate to
confirm and extend our results.
Association mapping (Figure 2)
(a) Orofacial was the only trait with an association exceeding genome-wide significance
(Figure 2A, chr5:42.3-44.4 Mb, P=1.6×10−6). This association was robust to analytical
method (Table 1). This region contains 12 known genes and 6 predicted genes, several of
which are expressed in brain (i.e. Cpeb2, Bst1). A search of the literature did not reveal any
immediate links between genes in this locus and haloperidol pharmacology, movement
disorders or monoamine neurotransmission. The second most significant peak was on chrX:
86.6-86.8 Mb (P=1.7×10−5), near Pit2 (plasmacytoma expressed transcript 2) which is
expressed in substantia nigra (Lagrue et al. 2010), a region thought to be affected in TD
(Chen et al. 2011). The third most significant peak occurred on chr9:91.8-92.0 Mb
(P=3.0×10−5), flanking two genes also expressed in brain motor control regions: Zic4 (zinc
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finger protein of the cerebellum 4) and Plscr1 (phospholipid scramblase 1). Finally, the
fourth most significant peak (chr13:53.912-53.914 Mb, P=4.6×10−5) was adjacent to the
dopamine receptor gene Drd1a, of great interest since haloperidol binds this receptor (Hsin-
tung E and Simpson 2000) and down-regulates it in pre-frontal cortex (Lidow and Goldman-
Rakic 1994). As with all of the Orofacial associations, this chr13 locus was seen with all
four analytical methods (Table 1). The individual strain genotypes for the top SNPs listed in
Table 1 are listed in Table S4.
(b) HAL30 (Figure 2B) had loci on chr6:50.92-51.02 Mb (P=1.1×10−5) and
chr15:23.54-25.64 (P=1.4×10−5) that narrowly missed reaching genome-wide significance.
Both of these peaks occurred in regions harboring genes of primarily unknown function.
Three other suggestive peaks were seen, two on chr17 and one on chr19. The chr19 peak
occurs within a liver-expressed anion exchanger, Slc26a8.
(c) EPS (Figure 2C) also had associations that narrowly missed permutation-based genome-
wide significance, including four peaks of similar magnitude on chr 2, 3, 11 and 12. The
significance threshold for EPS (8.7×10−13) was higher because this phenotype was
essentially dichotomous: 4 of 27 strains showed high levels of rigidity and three of these are
derived from New Zealand.
(d) OFA (Figure 2D) showed several peaks of similar height that failed to reach the
significance threshold. Two well-known neurodevelopmental genes Ncam2 (neuronal cell
adhesion molecule 2) and Plxna2 (plexin A2) were within these regions.
Pathway analysis
Since we analyzed complex genetic traits, and our sample size was relatively small, clear-cut
identification of genome-wide significant loci was perhaps unlikely. Some proportion of the
top loci could contain true signals that did not reach genome-wide significance due to low
power. Therefore, we ran pathway analysis on the top 1% of genes in each phenotype. Table
2 and Figures S5-S8 describe these networks. Many of these networks have biological
plausibility and some genes in these networks have known roles in movement disorders,
neurotransmission and drug absorption, distribution, metabolism and excretion (ADME).
For example, the Orofacial networks contained the primary receptor for haloperidol
(dopamine receptor D2, Drd2), two glutamate receptors (Grin1, Grin2a), the Huntington’s
disease gene (Htt), and Ncam1, as mentioned above.
For HAL30, only one network was significantly associated with the phenotype and it acts in
liver development and function. Data from humans indicate that about 40% of haloperidol is
subject to reabsorption via enterohepatic recycling (Eddington and Young 1990; Froemming
et al. 1989). Therefore, it is intriguing that at least one gene in this network, Abcc3
(multidrug resistance protein 3), is known to regulate biliary secretion. Slc4a4, also in this
pathway, modulates renal tubular pH which is a critical factor in drug elimination via urine.
EPS was also associated with a liver network, including the ADME-related genes Cyp17a1,
Slco1a2 and Abcc3. The second network contained genes that are mutated in human
neurological diseases: Grik1 (epilepsy), Wnt3a (neural tube defects), Mtmr7 (myotubular
myopathy). The top network for OFA listed a number of genes that, when knocked-out in
mice, result in abnormal behavior, including activity differences. These included the
glutamate receptors Grik2, Grin1 and Grin2a, and the calcium/calmodulin-dependent protein
kinase Camk2b (Mohn et al. 1999; Sakimura et al. 1995; Shaltiel et al. 2008; van Woerden
et al. 2009).
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Table 3 highlights published mouse QTLs that are within 5 Mb of an EMMA SNP with p ≤
0.0001; a 5 Mb window was used since most of these eQTLs were mapped using low
resolution crosses (F2 or BXD). It is intriguing that all three pharmacodynamic phenotypes
(Orofacial, EPS, OFA) share confidence intervals with at least 5 QTLs for compounds
which act directly (haloperidol, cocaine, methamphetamine) or indirectly (ethanol) on
dopaminergic neurotransmission.
We used the Sanger SNPs database to determine the functional consequence of each EMMA
SNP with p ≤ 0.0001. Furthermore, since the Sanger database has full genome sequence for
13 of our 27 strains, we were also able to identify genomic regions where the strain
distribution pattern matched our top EMMA SNPs (restricted to ± 40 kb from the EMMA
SNP). In this way, we identified hundreds of additional variants linked to the genotyped
SNP markers, including several putatively functional variants (see Table 4). With Orofacial,
for example, we found that a VCM-protective haplotype on chr5 is linked to a SNP in the 3′
UTR of Nkx6-1, a gene that plays an essential role in midbrain dopaminergic neuron
development (Prakash and Wurst 2006). In addition, we found that the strain with the
highest level of haloperidol-induced VCMs (DBA/2J) has two variants within the 5′ UTR of
striatum-expressed Plscr1 and a non-synonymous coding SNP within the predicted gene
EG624120.
CNV analysis
CNVs are another form of genetic variation that could explain the heritability of these traits.
We performed GWA with a set of 4,047 structural variants predicted to occur from Mouse
Diversity Array data from these strains. Table S5 lists the five most significant CNVs for
each phenotype after GWA and the corresponding genes with at least one exon lost or
gained due to deletion or duplication. For Orofacial, we found a strong relationship between
duplication of Mtch2 (mitochondrial carrier homolog 2) and increased haloperidol-induced
VCMs. The five strains with this duplication all fall within the top 9 strains in a 27-strain
ranking of the Orofacial variable. Duplication of Mtch2 is a plausible variant for
contributing to VCM susceptibility, given its role in apoptosis (Zaltsman et al. 2010) and the
possible role of neuroleptic-induced neuronal toxicity (via apoptosis) in TD (Galili et al.
2000; Mitchell et al. 2002; Skoblenick et al. 2006). With OFA, a deletion of Epha6 was
found in the two strains with the greatest haloperidol-induced decrease in activity (NZL and
NZW), and EPHA6 was associated with therapeutic response to the neuroleptic risperidone
(Ikeda et al. 2010). Furthermore, its expression was significantly increased in mouse frontal
cortex following chronic risperidone treatment (Ikeda et al. 2010).
Next, since SNPs are capable of tagging CNVs, we looked for overlap between CNVs and
the top 1% of SNP-associated loci for each phenotype (Table S6). A total of 6 variants, all
deletions, were found in the vicinity of the top SNPs, though only one of them resulted in
loss of exons. For Orofacial, a deletion on chr9 in the SM/J strain (which showed average
VCM susceptibility) was found to flank two genes mentioned above with expression in brain
motor control regions: Zic4 and Plscr1.
Gene expression analysis
Gene expression data can be used to prioritize regions for follow-up (Aylor et al. 2011).
Therefore, we sought to determine if brain gene expression correlated with any of the
phenotypes examined or with SNPs within EMMA-significant loci. We collected whole
brain tissue from mice that had been chronically treated with haloperidol for 120 days (the
same mice used in (Crowley et al. 2010)). Whole brain tissue was used because the
pathophysiology of EPS is thought to include several dispersed neuroanatomical regions
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(Koshikawa et al. 2011) and we found it more desirable to capture all regions rather than
microdissect a single region. Since the Crowley et al study did not have a placebo-treated
arm (but rather focused on differences before and after drug treatment) we did not have
tissue from untreated animals to use as a comparison group. We deemed it a worthwhile
experiment, however, since if haloperidol susceptibility was tightly linked to the expression
level of a particular transcript (or a set of transcripts in a biological pathway) after
haloperidol treatment, it should be detectable. We prioritized transcripts near: 1) top EMMA
SNPs that correlated with gene expression in cis, 2) the top 1% of genes in terms of
correlation between expression and phenotype, and 3) expression levels for the most
interesting candidate genes derived from the SNP GWAS, CNV GWAS and pathway
analysis.
First, we collected all probe sets within 1Mb of EMMA SNPs with p<0.0001, stratified gene
expression values by SNP genotype and tested for a significant expression difference
between the two genotypes. For each phenotype, a large number of genes showed evidence
of cis regulation (see Table S7). For example, with Orofacial we tested 287 probe sets and
61 were consistent with cis-regulation at a false discovery rate of 5%. Among these genes
were the dopamine receptor Drd1a, liver enzyme Cyp46a1, the cerebellar gene Zic4
mentioned above and also a related gene, Zic1. The other three phenotypes showed fewer
immediately obvious candidates.
Second, we examined the relationship between gene expression of the top 1% of associated
genes (Table S8) and phenotype. For Orofacial, this list included two synthetic enzymes and
one receptor binding partner for the primary inhibitory neurotransmitter in the brain, GABA
(Gad1, Gad2, Gabarapl2). HAL30 associated with several metabolic genes (i.e. Cyp2a22),
EPS correlated with several neurotransmitter-related genes including the dopamine-
transporting vesicular monoamine transporter 1 (Slc18a1) and OFA associated with a
number of genes that show brain expression, though of less-obvious relevance to
haloperidol.
Finally, we have identified many intriguing quantitative trait gene candidates through SNP
GWAS, CNV GWAS and pathway analysis. Table S9 lists association between gene
expression and phenotype for 27 such genes (the bold gene names in Tables 1, 2, S5). We
searched for genes whose expression level is among the top 20% of genes in terms of
association with the phenotype. First, two direct targets of haloperidol (Drd1 and Drd2) tend
to correlate with Orofacial. Six other genes identified by genetic analysis were similarly
linked to Orofacial, including the glutamate receptor gene Grin1. The HAL30 results are
more difficult to interpret for the reasons mentioned above, though the renal transporter
Slc4a4 fell within the top 20%. There was an interesting set of genes that we initially found
with Orofacial, but whose expression was correlated more with EPS (Cpeb2, Pet2, Ncam1,
Plscr1). This suggests the possibility of pleiotropic effects for these genes, regulating
susceptibility for two distinct haloperidol ADRs. Finally, OFA had three candidate genes in
the top 20%, including the risperidone-responsive gene Epha6.
Discussion
The purpose of this report was to investigate the genetics of several haloperidol-associated
phenotypes with the eventual goal of improving understanding of the genomics of human
TD. If VCMs are a reasonable analogue of TD, then it might be possible to accelerate
discovery by using a design whereby mouse genetic mapping resources are used to screen
the genomic search space to derive high-probability targets whose orthologs can be studied
in human samples. In this way, the multiple testing burden is paid in a relatively inexpensive
and experimentally tractable system and human samples are used only for testing candidate
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targets. To achieve this end, we selected optimal phenotypes from Crowley et al (Crowley et
al. 2010), and took a comprehensive genomic analysis approach.
First, we mapped QTL for haloperidol-response using 27 inbred strains and 426,493 SNPs.
This approach led to QTL of much higher resolution than with traditional mouse mapping
methods, which have employed populations with lower diversity (i.e. F2 cross or BXD
recombinant inbred lines) and lower density genotyping (~500 markers). For example, our
largest locus spans just 2.1 Mb (HAL30 association on chr15), while the confidence
intervals from traditional mouse QTL studies can easily cover 20 Mb and include hundreds
of genes. Our top peaks pointed to a number of interesting genes, only one of which has ever
been included in a TD candidate gene study (Drd1). For our three pharmacodynamic traits,
we identified genes expressed in the striatum (Plscr1, Bche, Drd1), neurodevelopmental
regulators (Ncam2, Plxna2), a key cerebellum gene (Zic4) and ~20 genes of currently
unknown function.
Second, we performed pathway analysis using our top GWA loci. The top networks for each
phenotype were consistent with the phenotypes, suggesting that our top loci contained true
signal, but did not reach genome-wide significance due to low power. Also consistent with
this idea is the presence of haloperidol’s primary receptor (Drd2) within the second
Orofacial network. As mentioned in the results, pathway analysis revealed a number of
additional genes that are plausible candidates for TD/EPS, including three glutamate
receptors (Grik2, Grin1, Grin2a) and genes known to cause neurological disease (Grik1,
Wnt3a, Mtmr7). As for haloperidol plasma levels, our overall pattern of results seem to
suggest a role for enterohepatic recycling, perhaps via Abcc3 (multidrug resistance protein
3).
Third, we collected a wealth of bioinformatic data on the top peaks of interest. When we
looked at the published mouse QTLs surrounding our top SNPs, it was reassuring how many
of these were related to dopaminergic drug response. All three of our pharmacodynamic
phenotypes shared confidence intervals with at least five QTLs for compounds which act on
dopamine (haloperidol, cocaine, methamphetamine, ethanol), while HAL30 shared no QTLs
with these compounds. This congruence is encouraging, but the ultimate goal of QTL
studies is to identify the causal quantitative trait nucleotide (QTN) underlying the QTL
(Mackay et al. 2009). Identification of the QTN has been the rate-limiting step in traditional
mouse complex trait studies, owing in part to a lack of polymorphism data genome-wide.
However, increasing amounts of genomic data in mice make this task straight-forward to
search for variants with a strain distribution pattern consistent with causality. We used the
Sanger database to identify hundreds of additional variants linked to the genotyped SNP
markers, including several putatively functional variants. Of particular interest was a VCM-
protective haplotype on chr5 linked to a SNP in the 3′ UTR of Nkx6-1, a gene required for
midbrain dopaminergic neuron development (Prakash and Wurst 2006). It is conceivable
that altered dopaminergic function via polymorphism in Nkx6-1 could predispose mice to
haloperidol-induced adverse drug reactions.
Fourth, we tested whether CNVs affected these traits. We performed GWA with a set of
4,047 structural variants known to occur in these strains and also looked for overlap between
CNVs and the top 1% of SNP-associated loci. In the CNV GWA, we found a strong
relationship between duplication of the Mtch2 (mitochondrial carrier homolog 2) gene and
increased haloperidol-induced VCMs. This is interesting given the role of Mtch2 in
apoptosis and the literature implicating neuroleptic-induced neuronal toxicity (via apoptosis)
in the development of TD (Galili et al. 2000; Mitchell et al. 2002; Skoblenick et al. 2006). In
addition, the relationship between a deletion of Epha6 and haloperidol-induced decreased
activity is intriguing given the results of a recent clinical study linking this gene to
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risperidone treatment response (Ikeda et al. 2010). Finally, it was notable that the liver-
expressed gene Supt3h was deleted in two strains with high plasma drug levels.
Finally, we examined the relationship between our findings and brain gene expression
following withdrawal from chronic haloperidol treatment. This extra step provided a
plausible method for prioritizing candidate genes within our top loci for follow-up. For
example, since Drd1a is located within one our top Orofacial loci and is cis-regulated, it is
reasonable to hypothesize that gene regulatory variation in this gene could underlie the QTL.
In conclusion, we have identified ~50 genes that we expect to have high prior probabilities
for association with haloperidol-induced TD. Furthermore, since the human genome
contains ~25,000 genes, we have provided a logical rationale for focusing on just a small
fraction (0.2%) of that genomic search space. As such, the multiple testing penalty is
reduced 500-fold.
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Phenotypic data from Crowley et al (Crowley et al. 2010) selected for genetic analysis. The
strains are sorted, left to right, in order of increasing haloperidol response (or plasma drug
level). The x-axis lists strain name (with the number of animals tested in parentheses) and y-
axis gives the phenotypic value for A) Orofacial, B) HAL30, C) EPS and D) OFA.
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Genome-wide association results from EMMA for A) Orofacial, B) HAL30, C) EPS and D)
OFA. Chromosome position is on the x-axis and the −log P value is on the y-axis. The
dashed horizontal line indicates the permutation-based genome-wide significance level,
which is unique for each phenotype.
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